Diabetes Mellitus Treatment Durg Sitagliptin Cas Number 486460-32-6

Basic Info

Model No.: 486460-32-6

Additional Info

Packaging: 25KGS/DRUM

Productivity: 40T/Y

Brand: VOLSENCHEM

Transportation: Ocean,Land,Air

Place of Origin: CHINA

Product Description

Sitagliptin cas number is 486460-32-6 listed in the United States on October 2006, followed by listing in countries such as Europe. In October 2007, sitagliptin was approved by the U.S. FDA for use with metformin. Currently in clinical use of anti-diabetic drugs are mainly insulin, sulfonylureas, metformin and recently listed α-glucosidase inhibitors and insulin sensitizers thiazolidinediones and other drugs. These drugs have good curative effect, but there are still has shortcomings of long-term use of drugs that can not maintain long-term efficacy, and easily lead to hypoglycemia, weight gain and liver toxicity and other adverse reactions. Sitagliptin cas 486460-32-6 is the first DPP-4 inhibitor to be approved for the treatment of type 2 diabetes, inhibiting beta-cell apoptosis, promoting beta-cell neogenesis, increasing beta-cell count in patients with type 2 diabetes, and significantly reducing blood glucose levels in patients Sulfanilamide patients still have significant hypoglycemic effects. Sitagliptin mainly controls glycemic in patients with type 2 diabetes through a combination of exercise and diet control. In recent years, with the continuous improvement of people's living standard and the change of diet structure, the number of diabetic patients has also witnessed a large-scale increase in some developing countries. According to data published by the International Diabetes Federation (IDF) on Diabetes Mellitus and Impaired Glucose Tolerance (IGT), the number of diabetic patients in 2003 was 194 million, reaching 333 million by 2025 and 472 million by 2025.

Thera. Category: Anti-Diabetes

Cas No.:486460-32-6

Synonym:Sitagliptin (3R)-3-Amino-1-[3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,2,4-triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one;Sitagliptin base;(3R)-3-Amino-1-[3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,2,4-triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one;Sitagliptin;1,2,4-Triazolo(4,3-A)pyrazine, 7-((3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl)-5,6,7,8-tetrahydor-3-(trifluoromethyl)-;Hsdb 7516;(3R)-3-AMino-1-[3-(trifluoroMethyl)-5,6,7,8-tetrahydro-1,2,4-riazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-rifluorophenyl) butan-1-one;(R)-3-amino-1-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-4-(2,4,5-trifluorophenyl)butan-1-one;

Molecular Structure:  

Molecular Formula:C16H15F6N5O

Molecular Weight: 407.32

Pharmacopeia: In house Spec.

Specifications:Available on request

Packing:Export worthy packing

Material Safety Data Sheet:Available on request